ArticleMalaria journal2025
A cross-sectional survey of Plasmodium falciparum and Plasmodium vivax in India using rapid diagnostic test and microscopy across 12 sites of varying transmission, 2023-2024.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
backgroundIn India, Plasmodium falciparum and Plasmodium vivax remain in circulation. Accurate detection of the parasite species remains crucial for prompt initiation of treatment and reducing onward transmission.
methodsA cross-sectional study across 12 sites of varying malaria endemicities was conducted from September 2023 to April 2024. Febrile participants were tested for malaria using rapid diagnostic tests (RDTs) and microscopy. Malaria positivity proportions along with 95% confidence intervals (95% CI) were presented separately by parasite species. The diagnostic performance of the RDT was compared against microscopy.
resultsA total of 10,290 febrile participants were tested by both RDT and microscopy: 1,516 (14.7%, 95% CI 7.7-21.8%) malaria cases were identified by RDT and 1,436 (14.0%, 95% CI 6.9-21.1%) by microscopy. Of the 1,516 RDT positives, 1,105 (72.9%) had P. falciparum mono-infection, 290 (19.1%) had P. vivax mono-infection, and 121 (8.0%) had P. falciparum and P. vivax mixed infections. The sensitivity and specificity of RDT were 95.0% [95% CI 94-96%] and 99% [95% CI 98-99%], respectively, for detecting P. falciparum mono-infection, 83% [95% CI 78-87%] and 100% [95% CI 99-100%] for detecting P. vivax mono-infection, and 88% [95% CI 80-93%] and 100% for detecting a mixed infection of P. falciparum and P. vivax. Overall, 43 (0.4%) participants who were RDT negative were found to have malaria on subsequent microscopic examination.
conclusionApproximately 15% of the febrile participants tested were identified as malaria positive by RDT, of which nearly one-fifth were P. vivax mono-infections and 8% harboured P. falciparum and P. vivax mixed infections. Low sensitivity of the RDTs for identifying P. vivax underscores an urgent need for developing reliable diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.